Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-1179 Versus Valacyclovir in Recurrent Genital Herpes
NCT07912996Phase 2Not yet recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2026
- Primary completion
- Nov 2027
01
Overview
Phase 2, randomised, double-blind trial of GS-1179 in genital herpes (3 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experiencing Adverse Events at 92 days, Percentage of Participants Experiencing Premature Study-Drug Discontinuation due to AEs at 92 days and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
GS-1179
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT07912996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07912996.